Recent Industry Misstatements about Implant-Cancer Research
"The majority of tumors [in the 1997 Tillmann study] were benign fibrosarcomas..."
- Destron Fearing, makers of the HomeAgain pet implant
Source: "Tissue Reactions to Microchip Implantation in Laboratory Animals
and Pets," page 2, column 2, paragraph 2.
There is no such thing as a "benign fibrosarcoma." All of the tumors found in the 1997 Tillmann study were malignant cancers. A fibrosarcoma is a type of sarcoma, a malignant tumor of soft tissue that connects, supports or surrounds other structures and organs of the body. Dr. Timothy Jennings, an expert on implant-induced cancers in humans, said he was "not aware of any nosology incorporating an entity of 'benign fibrosarcoma'" and agreed that "any tumor classified as sarcoma should be viewed as malignant."
Time Magazine writes: "In an exclusive interview with TIME, [Scott] Silverman [VeriChip CEO] provided [one of the studies] mentioned in the AP article, which showed that less than 1% of 4,279 chipped mice developed tumors "clearly due to the implanted microchips" but were otherwise healthy, and that "no clinical symptoms except the nodule on their backs were shown."
- Time Magazine, "Are Microchip Tags Safe?" by Siobhan Morrissey
October 18, 2007. _ at: http://www.time.com/time/health/article ... 65,00.html
The 1997 Tillmann study, to which this passage refers, reported that laboratory mice developed malignant cancers around the microchips that involved "extensive local invasion of the surrounding tissues" and "zones of necrosis and high mitotic activity." (p. 198) These mice can hardly be referred to as "healthy."
Time Magazine goes on to say, "The second study, conducted in France in 2006, two years after VeriChip's FDA application was approved, found that while 4% of the 1,260 mice in the study developed tumors, none of them were malignant."
The 2006 Le Calvez study, to which this passage refers, found that 4% of mice developed tumors surrounding or adjacent to the microchip implants. All tumors found were classified as sarcomas-- a malignant form of cancer. Not only were the tumors malignant, but the often infiltrated nearby muscle tissue, and several metastasized (spread) to the lungs, liver, stomach, or pancreas. Even more disturbingly, many of the implants migrated from the original implantation site on the backs of the mice to cause cancer at other locations in the body. Nineteen percent of the cancers found involved microchips that had migrated from the back to the limbs, abdomen, or head of the mice.
Time Magazine also writes: "As for the third study, Silverman says it was conducted in mice specifically bred to produce tumors, and was therefore omitted from the sheaf of studies included in the FDA application."
This statement was referring to genetically modified mice used in the 1999 Blanchard study. The p53+/- mouse is genetically modified to have an increased susceptibility to cancer only when exposed to genotoxins, or substances that damage genetic material. It is not known to develop spontaneous tumors in the absence of genotoxins within the first six months of life, when the microchip-induced tumors in this study arose.
The high rate of cancer development in these mice (10.2%) in just six months suggests that implanted microchips may have genotoxic attributes or give rise to the production of genotoxins in the host. The researchers stated that, "the presence of the foreign body [microchip implant] may elicit tissue reactions capable of generating genotoxic byproducts." This raises a serious red flag about the microchip. The data from this study should have been carefully considered by the FDA during its evaluation of the microchip. It was inappropriate and negligent to omit this information from the FDA application.